Showing results (951-960 of 6,317) with videos related to
Sort By:
Pageof 632
Diabetes, Obesity & Metabolism|April 11, 2023
A review of current key guidelines for managing high-risk patients with diabetes and heart failure and future prospectsMatthew M Y Lee, Naveed SattarDiabetes, Obesity & Metabolism|April 13, 2023
The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trialsJakob Bue Bjorner, Sara Larsen, Christopher Lübker, et al.Diabetes, Obesity & Metabolism|March 31, 2023
Impact of pre-existing type 2 diabetes with and without cardiovascular disease on patients with COVID-19Chi Nguyen, Christopher L Crowe, Effie Kuti, et al.Diabetes, Obesity & Metabolism|April 4, 2023
Association of glycation gap with all-cause and cardiovascular mortality in US adults: A nationwide cohort studyLingfeng Gu, Sibo Wang, Chong Du, et al.Diabetes, Obesity & Metabolism|March 30, 2021
Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trialWenhuan Feng, Wei Chen, Shan Jiang, et al.Diabetes, Obesity & Metabolism|March 17, 2015
Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitusE Araki, Y Tanizawa, Y Tanaka, et al.Diabetes, Obesity & Metabolism|April 8, 2021
Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100Anastasia-Stefania Alexopoulos, Andreas Andersen, Anders Meller Donatsky, et al.Diabetes, Obesity & Metabolism|April 9, 2021
Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetesShun Kohsaka, Masayoshi Takeda, Yoko Kidani, et al.Diabetes, Obesity & Metabolism|April 9, 2021
Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseasesIssei Komuro, Takashi Kadowaki, Johan Bodegård, et al.Diabetes, Obesity & Metabolism|August 7, 2012
The interaction of amylin with other hormones in the control of eatingT A LutzPageof 632